OTC · Biotechnology

Neuren Pharmaceuticals Limited (NURPF) Stock

$13.46 +0.00% OTC: NURPF Healthcare

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome.

Valuation

MetricValue
Price$13.46
Market Cap$1.71B
P/E Ratio68.94
P/B Ratio6.19
P/S Ratio32.45
EPS (TTM)$0.20
52-Week High$14.80
52-Week Low$7.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE9.20%
ROA8.88%
ROCE2.11%
Gross Margin76.93%
Operating Margin11.03%
Net Margin47.09%
Debt/Equity0.00
Current Ratio76.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$15.0M$232.0M$217.0M$65.0M
Operating Profit$-18.0M$-2.0M$172.0M$146.0M$22.0M
Net Profit$-8.0M$0$157.0M$142.0M$30.0M
EPS$-0.07$0.00$1.20$1.09$0.24
Op Margin-555.2%-11.0%74.4%67.4%34.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$43.0M$248.0M$410.0M$343.0M
Total Liabilities$1.0M$2.0M$43.0M$46.0M$4.0M
Cash$37.0M$40.0M$17.0M$3.0M$4.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$4.0M$185.0M$-11.0M$125.0M
Investing Cash Flow$0$0$-212.0M$4.0M$-88.0M
Financing Cash Flow$-1.0M$0$0$-9.0M$-40.0M
Net Cash Flow$13.0M$3.0M$-23.0M$-14.0M$1.0M
Free Cash Flow$-10.0M$4.0M$185.0M$-11.0M$125.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.88
EV / EBITDA94.94
FCF Yield5.98%
Quick Ratio76.60
Interest Coverage0.00
Return 1Y33.53%
Return 3Y36.12%
Return 5Y—

Ownership

Insiders Held13.34%
Institutions Held23.47%
Institutions Float Held27.09%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund1,556,4812026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund1,049,1612026-03-31
iShares Trust-iShares Core MSCI EAFE ETF859,3902026-06-30
American Century ETF Trust-Avantis International Small Cap Value ETF753,9402026-06-30
DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series597,8342026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
ASMB $26.68 +0.87% -51.53 $424.02M 0.00%
AVTEAerovate Therapeutics, Inc. $2.68 +0.00% 0.00 $77.68M 0.00%
CERECerevel Therapeutics Holdings, Inc. $44.96 +0.74% -16.84 $8.19B 0.00%
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%

About Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes. In addition to its drug pipeline, Neuren provides development-related services and possesses investments in loan-backed shares. The firm was established in 2001 and operates from its base in Camberwell, Australia.

Neuren Pharmaceuticals Limited is headquartered in AU.

Neuren Pharmaceuticals Limited (NURPF) stock trades at $13.46 with a market capitalization of $1.71B. The stock is valued at a price-to-earnings (P/E) ratio of 68.94, price-to-book of 6.19, price-to-sales of 32.45. Over the past 52 weeks the stock has ranged between $7.70 and $14.80, and currently trades 9.1% below its 52-week high.

On profitability, Neuren Pharmaceuticals Limited generates a return on equity (ROE) of 9.20%, return on capital employed of 2.11%, an operating margin of 11.03%, a net profit margin of 47.09%.

Official website: www.neurenpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides